Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

41 ta ish

Ish: DISTRIBUTION OF POLYMORPHISMS OF GENES OF STATINS METABOLISM AND TRANSPORT IN THE LIVER IN PATIENTS WITH CORONARY ARTERY DISEASE ETHNIC UZBEKS WITH SIMVASTATIN INTOLERANCE

  1. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

    Colin Baigent, Anthony Keech, Patricia M. Kearney +8

    Sharh maqola20057 iqtibos
    ABI

  2. Sarlavhasiz

    Boshqa5 iqtibos
    ABI

  3. <i>SLCO1B1</i> Variants and Statin-Induced Myopathy — A Genomewide Study

    The SEARCH Collaborative Group

    Maqola20084 iqtibos
    ABI

  4. Lipid-lowering response to statins is affected by CYP3A5 polymorphism

    Kari T. Kivistö, Mikko Niemi, Elke Schaeffeler +6

    Maqola20044 iqtibos
    ABI

  5. Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects

    William E. Evans, Howard L. McLeod

    Maqola20034 iqtibos
    ABI

  6. Effect of Polymorphic <i>CYP3A5</i> Genotype on the Single‐Dose Simvastatin Pharmacokinetics in Healthy Subjects

    Kyoung‐Ah Kim, Pil‐Whan Park, Ock‐Je Lee +2

    Maqola20064 iqtibos
    ABI

  7. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000

    Earl S. Ford, Umed A. Ajani, Janet B. Croft +5

    Maqola20073 iqtibos
    ABI

  8. <i>CYP3AP1*3</i>Allele Is Associated With Lipid-Lowering Efficacy of Simvastatin and Atorvastatin in Chinese Women

    Yanpeng Li, Lirong Zhang, Min Jia +1

    Maqola20103 iqtibos
    ABI

  9. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment

    Marilu Fiegenbaum, F DASILVEIRA, C VANDERSAND +4

    Maqola20053 iqtibos
    ABI

  10. CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort

    Joseph P. Kitzmiller, Jasmine A. Luzum, Damiano Baldassarre +2

    Maqola20143 iqtibos
    ABI

  11. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity

    Fumihiro Sata

    Maqola20003 iqtibos
    ABI

  12. Needed: Pragmatic Clinical Trials for Statin-Intolerant Patients

    Patricia D. Maningat, Jan L. Breslow

    Maqola20113 iqtibos
    ABI

  13. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

    Marja K. Pasanen, Mikko Neuvonen, Pertti J. Neuvonen +1

    Maqola20063 iqtibos
    ABI

  14. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

    Peter Kuehl, Jiong Zhang, Yvonne Lin +16

    Maqola20013 iqtibos
    ABI

  15. Sarlavhasiz

    Boshqa3 iqtibos
    ABI

  16. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study

    Laure Elens, Matthijs L. Becker, Vincent Haufroid +5

    Maqola20112 iqtibos
    ABI

  17. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

    Daqing Wang, Yingying Guo, Steven Wrighton +2

    Maqola20102 iqtibos
    ABI

  18. Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction

    Kristian Bailey, Simon P.R. Romaine, Beryl M. Jackson +12

    Maqola20102 iqtibos
    ABI

  19. ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

    Jenni E. Keskitalo, Oliver Zolk, Martin F. Fromm +3

    Maqola20092 iqtibos
    ABI

  20. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  21. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  22. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  23. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  24. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  25. Sarlavhasiz

    Boshqa2 iqtibos
    ABI